BioSpace News Archive

Evaluable participants (n=20) are heavily pretreated (median of 3 prior lines of treatment); an increase in progression-free survival is a desired outcome

Phio Pharmaceuticals Corp., a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi therapeutic platform, announced new in vivo data showing intratumoral treatment with the murine PD-1 targeting INTASYL inhibits tumor growth in a dose dependent fashion in PD-1 responsive and refractory models.

Results further support the investigation of monotherapy seribantumab for the treatment of solid tumors uniquely driven by an NRG1 fusion in the ongoing Phase 2 CRESTONE study

The study validates that ecDNA is a driver of cancer by providing a fitness advantage for tumor cells through oncogene copy number amplification and oncogene dependency switching

First pivotal study to compare Peptide Receptor Radionuclide Therapy (PRRT) in patients with Grade 1 and 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with approved standard of care

Findings to be Presented at AACR Annual Meeting Further Demonstrate the Utility of Protein Biomarker Data to Support Physicians in Patient Management

Bicycle Therapeutics plc announced that for the first time, preclinical work describing the discovery of BT7480, a novel Nectin-4/CD137 tumor-targeted immune cell agonist, will be presented virtually in a “New Drugs on the Horizon” session at the American Association for Cancer Research Annual Meeting, taking place April 10-15, 2021.

Xencor, Inc. announced the presentation of new data from multiple preclinical XmAb® bispecific antibody programs and its preclinical IL-12-Fc cytokine program at the American Association for Cancer Research Annual Meeting, being held virtually April 10-15, 2021.

Synthekine Inc., an engineered cytokine therapeutics company, announced preclinical data presented at the American Association of Cancer Research Annual Meeting 2021 demonstrating its alpha/beta selective IL-2 partial agonist, STK-012, induced potent anti-tumor activity while avoiding the toxicities that have hindered the development of IL-2 therapeutics, including vascular leak syndrome.

Ultimovacs ASA, announced that it is presenting a poster on the trial design of its ongoing Phase II INITIUM clinical study evaluating nivolumab and ipilimumab in combination with the Company’s proprietary universal cancer vaccine, UV1, as first line treatment in patients with metastatic malignant melanoma, at the 2021 AACR Annual Meeting, held virtually from April 9 to April 14, 2021.